2C-D (2,5-dimethoxy-4-methylphenethylamine) is a psychedelic phenethylamine of the 2C family, first synthesized by a team at the Texas Research Institute of Mental Sciences in 1970 and later characterized in depth by Alexander Shulgin . Shulgin famously described 2C-D as "pharmacological tofu" — not because it lacks activity, but because at lower doses it tends to absorb and amplify whatever else is present in the experience, much like tofu takes on the flavor of the ingredients around it . This quality made it a favorite potentiator and extender in Shulgin's research toolkit.
At threshold to low doses (10-15 mg orally), 2C-D produces a subtle, clear-headed enhancement that many describe as nootropic in character — heightened visual acuity, improved verbal fluency, and a gentle uplift in mood without the perceptual distortions typical of stronger psychedelics . At common to strong doses (25-50 mg), the compound reveals its full psychedelic nature: open- and closed-eye visuals, enhanced pattern recognition, and a warm, empathogenic headspace that remains notably lucid compared to relatives like 2C-B or 2C-E .
The experience typically lasts 4 to 6 hours with a gentle comedown, making it one of the more manageable members of the 2C family. Its forgiving dose-response curve and low body load have contributed to its reputation as an excellent introductory psychedelic and a useful tool for therapeutic or introspective settings. Shulgin rated it "plus two" at 20-25 mg in PiHKAL, noting its analytical, insightful quality over raw intensity .
References
- Shulgin, A.T. & Shulgin, A. PiHKAL: A Chemical Love Story. Transform Press, 1991.
- Shulgin, A.T. PiHKAL entry #23: 2C-D. Erowid Online Library.
- Trachsel, D. et al. "Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines." Psychopharmacology, 231(18), 2014.
Safety at a Glance
High Risk- C-not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
- Australia: Australia has a blanket ban over all substituted phenethylamines including the entire 2C-X family.
- Toxicity: The toxicity and long-term health effects of recreational 2C-D use do not seem to have been studied in any scientific...
- Overdose risk: Fatal overdose from 2C-D alone, at doses within the typical recreational range, is extremely unli...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 3 hrs – 5 hrsHow It Feels
The onset is clean and crisp, arriving within thirty to forty-five minutes as a subtle sharpening of mental focus. Before any visual changes become apparent, there is a cognitive shift -- thoughts feel slightly more organized, connections between ideas come a fraction faster, and there is a gentle brightening of attention that resembles a mild nootropic more than a psychedelic. The body responds with a light, pleasant stimulation: a modest energy boost without jitteriness, a slight warming of the skin, and a relaxation of baseline muscular tension. The stomach is largely untroubled.
As the experience develops over the next hour, visual effects gradually emerge at the edges of perception. Colors become warmer and slightly more saturated. Surfaces may develop the faintest breathing motion -- barely perceptible unless attention is directed toward it. At lower doses, the visual component remains so subtle that it could be mistaken for the heightened aesthetic sensitivity that comes with a good mood and fresh attention. At moderate doses, gentle geometric patterns may appear against plain surfaces -- soft, flowing forms in warm earth tones that shift slowly and pleasantly. The overall visual character is understated and tasteful, enhancing rather than overwhelming the ordinary appearance of things.
The headspace is the defining feature of 2C-D. It is clean, lucid, and gently expansive. The cognitive enhancement that characterized the onset persists and deepens -- creative thinking feels more fluid, analytical processes feel slightly more capable, and there is a broadening of perspective that lends itself to productive reflection without the emotional intensity or destabilizing ego effects of stronger psychedelics. Many users describe it as thinking more clearly rather than thinking differently. There is a mild euphoria and a quiet appreciation for the present moment. Music is subtly enhanced, and conversations feel easy and engaging. The body remains comfortable throughout, with minimal load.
Effects begin to diminish around three to four hours after onset. The cognitive enhancement fades gradually, and the faint visual effects dissolve back to baseline. The comedown is essentially imperceptible -- there is no crash, no depletion, and no physical aftermath to speak of. Total duration spans four to six hours. 2C-D is often described as the most functional member of the 2C family, valued less for its psychedelic depth than for the gentle clarity and creative openness it provides. It is the substance equivalent of polishing a lens rather than replacing it.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(10)
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(17)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Autonomous entity— The perception of contact with seemingly sentient, independently acting beings that appear within ha...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- External hallucination— A visual hallucination that manifests within the external environment as though it were physically r...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Recursion— The visual field begins to repeat and nest within itself in a self-similar, fractal-like manner, as ...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(16)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Panic attack— A panic attack is a discrete episode of acute, overwhelming fear or terror that arises suddenly and ...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
Multi-sensory(2)
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(4)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Entity contact— Perception of encountering autonomous beings or presences during psychedelic states, ranging from va...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Receptor Pharmacology
2C-D exerts its psychoactive effects primarily through agonism at serotonin 5-HT2A and 5-HT2C receptors, the canonical targets for classical psychedelics . However, compared to more potent family members like 2C-B or 2C-E, 2C-D displays notably lower efficacy and potency at these receptors — functioning as a partial agonist with relatively modest intrinsic activity .
Binding studies place 2C-D's affinity at the 5-HT2A receptor with pEC50 values around 5.09, and at 5-HT2C around 4.73 — substantially weaker than compounds like DOI or 2C-B . Interestingly, 2C-D shows slightly higher affinity for the 5-HT2C receptor subtype than 5-HT2A, and achieves full agonist activity at 5-HT2C while remaining a partial agonist at 5-HT2A . It also displays partial agonist activity at 5-HT2B receptors .
Dose-Dependent Pharmacological Shift
One of 2C-D's most pharmacologically interesting features is the qualitative shift in its effects across the dose range. At low doses (under 15 mg), the compound's weak 5-HT2A partial agonism produces effects more consistent with enhanced serotonergic tone — improved mood, sharpened cognition, and subtle sensory enhancement without overt psychedelia . This has led to interest in 2C-D as a potential nootropic or cognitive enhancer at sub-psychedelic doses.
At higher doses (25-50 mg), sufficient receptor occupancy is achieved to produce classical psychedelic effects mediated by 5-HT2A activation — visual distortions, altered thought patterns, and ego softening — though these remain milder than equipotent doses of 2C-B .
Monoamine Interactions
Like other 2C compounds, 2C-D shows weak inhibitory activity at monoamine oxidase A (MAO-A), though this effect is not considered clinically significant at typical doses . The compound demonstrates minimal affinity for dopamine and norepinephrine transporters, which contributes to its relatively gentle stimulant profile .
References
- Rickli, A. et al. "Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives." Biochemical Pharmacology, 2015.
- Eshleman, A.J. et al. "Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines." Psychopharmacology, 231(18), 2014. PMC3945162.
- Shulgin, A.T. & Shulgin, A. PiHKAL: A Chemical Love Story. Transform Press, 1991.
- Wagmann, L. et al. "Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases." Drug Testing and Analysis, 11(2), 2019.
Detection Methods
Urine Detection
2C-D is not specifically targeted by standard immunoassay-based urine drug panels. However, because 2C-x phenethylamines share structural features with amphetamines, they may trigger false positives on amphetamine immunoassays in some cases. The likelihood of cross-reactivity depends on the specific immunoassay manufacturer and the antibody selectivity used. Urine detection windows for 2C-D are estimated at 24 to 72 hours following ingestion when analyzed by LC-MS/MS methods, though limited pharmacokinetic data exists for many 2C-x compounds.
Blood and Serum Detection
Blood detection windows for 2C-D are approximately 6 to 24 hours after oral administration. Peak plasma concentrations typically occur 1 to 3 hours post-ingestion. The relatively short half-lives of most 2C-x phenethylamines mean that blood testing must be performed promptly to capture detectable concentrations. LC-MS/MS is the only reliable method for quantitative blood analysis.
Standard Drug Panel Inclusion
2C-D is NOT specifically included on standard 5-panel, 10-panel, or 12-panel drug screens. The primary concern for individuals undergoing routine screening is the potential for amphetamine cross-reactivity on immunoassay-based panels. If a presumptive positive for amphetamines occurs, confirmatory testing by GC-MS or LC-MS/MS would not confirm amphetamine and the result would be reported as negative unless the laboratory specifically tests for 2C-x compounds. Most routine laboratories do not include 2C-x phenethylamines in their confirmatory panels.
Confirmatory Methods
Definitive identification of 2C-D requires LC-MS/MS or GC-MS with appropriate reference standards. Some forensic toxicology laboratories include 2C-x phenethylamines in their extended novel psychoactive substance panels. Immunoassay cross-reactivity alone is insufficient for confirmation and would be resolved by standard confirmatory procedures. Quantitative analysis typically requires specific method development as these compounds are not part of routine clinical chemistry workflows.
Reagent Testing (Harm Reduction)
For harm reduction identification, the Marquis reagent is a primary screening tool for 2C-D. The Marquis reagent produces a green to dark green reaction with 2C-D. The Mecke reagent may provide additional color reactions that help differentiate between specific 2C-x variants. The Ehrlich reagent shows no reaction with 2C-x phenethylamines, which can help distinguish them from tryptamines and lysergamides. The Mandelin reagent may produce green to brown reactions depending on the specific compound. Using multiple reagents in combination provides the most reliable field identification, though reagent testing cannot determine purity or dosage.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Synthesis and Early Research
2C-D was first synthesized in 1970 by researchers at the Texas Research Institute of Mental Sciences as part of a systematic exploration of substituted phenethylamines . However, its psychoactive properties went unrecognized until Alexander Shulgin began personally testing the compound in the mid-1970s. Shulgin conducted initial sub-threshold trials in 1964 with related structures, and between 1974 and 1978 he and his research circle carried out detailed bioassays of 2C-D at escalating doses, establishing its dose-response profile from subtle cognitive enhancement to full psychedelic activity .
PiHKAL and the "Pharmacological Tofu"
Shulgin documented 2C-D as entry #23 in his landmark 1991 book PiHKAL: A Chemical Love Story, describing its synthesis, dosage ranges (20-60 mg oral), and subjective effects . It was here that he coined the memorable description "pharmacological tofu," capturing the compound's unique ability to serve as a neutral amplifier of other psychoactive experiences rather than imposing its own strong character . This characterization cemented 2C-D's reputation within the research chemical community as a tool compound — valued for potentiation and combination work rather than standalone use.
Legal Status
2C-D has been scheduled in several jurisdictions. It is not individually named in the United States' Controlled Substances Act but falls under the Federal Analogue Act when intended for human consumption. Several countries including Germany, the United Kingdom, and Australia have explicitly scheduled the compound .
References
- Ho, B.T. et al. Texas Research Institute of Mental Sciences phenethylamine studies, 1970.
- Shulgin, A.T. & Shulgin, A. PiHKAL: A Chemical Love Story. Transform Press, 1991.
- Dean, B.V. et al. "2C or Not 2C: Phenethylamine Designer Drug Review." Journal of Medical Toxicology, 9(2), 2013. PMC3657019.
Harm Reduction
2C-not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 2C-almost immediately after ingestion. After that,37 days to be back at baseline (in the absence of further consumption). 2C-D presents cross-tolerance with Cross-all psychedelics, meaning that after the consumption of 2C-D all psychedelics will have a reduced effect.
- Australia: Australia has a blanket ban over all substituted phenethylamines including the entire 2C-X family.
- Austria: 2C-D is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich). In its Schedule II, the further specifying NPSV (Neue-Psychoaktive-Substanzen-Verordnung Österreich) explicitly bans all substituted phenetylamines.
- Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
- Canada: 2C-D would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
- China: 2C-D is a controlled substance in China as of October 2015.
- Denmark: 2C-D is added to the list of Schedule B controlled substances.
- Germany: 2C-D is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
- Japan: 2C-D is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.
- Latvia: 2C-D is a Schedule I controlled substance.
- The Netherlands:** 2C-D is currently legal, but it is part of a substance group that may be banned soon as part of a recently passed la
Toxicity & Safety
The toxicity and long-term health effects of recreational 2C-D use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 2C-D is a research chemical with very little history of human usage.
Anecdotal evidence from those within the community who have tried 2C-D suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
2C-D is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 2C-D is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 2C-D presents cross-tolerance with all psychedelics, meaning that after the consumption of 2C-D all psychedelics will have a reduced effect.
Dangerous interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
Lithium - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
Cannabis - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of 2C-D. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
Stimulants - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.
Tramadol - Tramadol is well-documented to lower the seizure threshold and psychedelics may act to trigger seizures in susceptible individuals.
Addiction Potential
not habit-forming
Overdose Information
Fatal overdose from 2C-D alone, at doses within the typical recreational range, is extremely unlikely based on the available evidence for classical psychedelics. The therapeutic index for most psychedelics is very wide.
However, psychological emergencies can occur and require appropriate response:
- Severe anxiety, panic, or psychotic episodes
- Dangerous behavior due to impaired reality testing
- Self-harm in the context of a distressing experience
Emergency management: If someone is experiencing a severe adverse reaction, move them to a calm, quiet environment. Speak reassuringly. Do not restrain unless there is immediate danger. Benzodiazepines (if available and the person is conscious and able to swallow) can reduce acute anxiety. If psychotic symptoms, self-harm risk, or medical distress is present, seek emergency medical attention.
Medical attention: Seek help immediately for seizures, extremely elevated body temperature, signs of serotonin syndrome (agitation, tremor, diarrhea, rapid heart rate), or if the substance consumed is uncertain.
Tolerance
| Full | almost immediately after ingestion |
| Half | 3 days |
| Zero | 7 days |
Cross-tolerances
Legal Status
Australia: Australia has a blanket ban over all substituted phenethylamines including the entire 2C-X family.
Austria: 2C-D is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich). In its Schedule II, the further specifying NPSV (Neue-Psychoaktive-Substanzen-Verordnung Österreich) explicitly bans all substituted phenetylamines.
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
Canada: 2C-D would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
China: 2C-D is a controlled substance in China as of October 2015.
Denmark: 2C-D is added to the list of Schedule B controlled substances.
Germany: 2C-D is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Japan: 2C-D is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.
Latvia: 2C-D is a Schedule I controlled substance.
The Netherlands:** 2C-D is currently legal, but it is part of a substance group that may be banned soon as part of a recently passed law on New Psychoactive Substances (NPS).
Sweden: 2C-D is classified as a health hazard as of March 1, 2005, in the regulation SFS 2005:26, making it illegal to sell or possess.
Switzerland: 2C-D is a controlled substance specifically named under Verzeichnis E.
Turkey:** 2C-D is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: 2C-D is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.
United States: 2C-D is listed in Schedule I of section 202(c) of the Controlled Substances Act in the United States. This was signed into law as of July 2012 under the Food and Drug Administration Safety and Innovation Act.
Responsible use
Psychoactive substance index
Psychedelics
Phenethylamines
2C-x
2C-D (Wikipedia)
2C-D (Erowid Vault)
2C-D (PiHKAL / Isomer Design)
Forums
2C-D (Bluelight)
Experience Reports (4)
Tips (9)
People with a personal or family history of psychotic disorders (schizophrenia, bipolar type I) should avoid 2C-D and other psychedelics. These substances can trigger or exacerbate psychotic episodes in predisposed individuals.
Clear your schedule for the full duration of 2C-D plus afterglow. Do not plan any obligations, driving, or important decisions for the day. Having a time pressure or commitment hanging over you adds unnecessary anxiety.
2C-D is excellent for hiking and outdoor activities due to its clearheaded nature. Even at moderate doses the headspace remains lucid and insightful without the confusion or mindfuckery common to stronger psychedelics. Effects last only 3-4 hours.
2C-D was described by Alexander Shulgin as a pharmacological tofu that takes on the flavor of whatever it is combined with. On its own at low doses it provides mild stimulation and cognitive clarity, making it useful as a creative tool.
2C-D has an unusually wide dose range. Effects at 10-20mg are subtle and nootropic-like, 30-50mg produces a light clearheaded trip with mood lift and sparkly visuals, and 75-100mg+ is needed for a fully visual psychedelic experience. Start around 30-40mg for a first genuine trip.
If you experience anxiety or thought loops on 2C-D, change your physical environment: move to a different room, go outside, change the music, or hold something cold. A change of scenery can instantly shift a difficult headspace.
Community Discussions (1)
See Also
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 2C-D - TripSit Factsheet
TripSit factsheet for 2C-D
tripsit - 2C-D - Wikipedia
Wikipedia article on 2C-D
wikipedia